ZURICH: Roche’s Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines. The European Commission approved Tecentriq with …